X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
oncology (10) 10
cancer (7) 7
chemotherapy (7) 7
female (7) 7
middle aged (7) 7
adult (6) 6
aged (6) 6
index medicus (6) 6
male (5) 5
carcinoma, squamous cell - drug therapy (4) 4
disease-free survival (4) 4
hematology, oncology and palliative medicine (4) 4
tumors (4) 4
aged, 80 and over (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
head and neck neoplasms - drug therapy (3) 3
prognosis (3) 3
squamous cell carcinoma of head and neck (3) 3
treatment outcome (3) 3
acquired-resistance (2) 2
afatinib (2) 2
analysis (2) 2
antibodies, monoclonal - pharmacology (2) 2
antibody (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - pharmacology (2) 2
biomarkers, tumor - analysis (2) 2
bisphosphonates (2) 2
cancer therapies (2) 2
carcinoma (2) 2
care and treatment (2) 2
cell line, tumor (2) 2
cetuximab (2) 2
cetuximab resistance (2) 2
cytotoxicity (2) 2
drug therapy (2) 2
head and neck cancer (2) 2
head and neck squamous cell carcinoma (2) 2
human medicine (2) 2
human papillomavirus (2) 2
jaw diseases - diagnostic imaging (2) 2
kinases (2) 2
mehd7945a (2) 2
neoplasm recurrence, local - drug therapy (2) 2
onj (2) 2
osteonecrosis (2) 2
osteonecrosis - diagnostic imaging (2) 2
pharmacology & pharmacy (2) 2
prospective studies (2) 2
quinazolines - administration & dosage (2) 2
radiation therapy (2) 2
radiology, nuclear medicine & medical imaging (2) 2
recurrent (2) 2
risk factors (2) 2
solid tumors (2) 2
squamous cell carcinoma (2) 2
squamous-cell carcinoma (2) 2
studies (2) 2
survival rate (2) 2
therapy (2) 2
accelerated radiation-therapy (1) 1
advanced resectable head (1) 1
aflibercept (1) 1
age factors (1) 1
anti-egfr therapy (1) 1
anti-vegf (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antibodies, monoclonal, humanized - pharmacology (1) 1
antineoplastic agents, immunological - pharmacology (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - pharmacology (1) 1
apigenin induces apoptosis (1) 1
apoptosis - drug effects (1) 1
aurora kinase b (1) 1
aurora kinase b - metabolism (1) 1
aurora kinases (1) 1
bemp (1) 1
biomarker (1) 1
biomarkers (1) 1
biotechnology (1) 1
bisphosphonate (1) 1
bisphosphonate-related osteonecrosis (1) 1
bleomycin - therapeutic use (1) 1
blockage (1) 1
bone density conservation agents - administration & dosage (1) 1
bone density conservation agents - adverse effects (1) 1
bone scintigraphy (1) 1
bone turnover (1) 1
breast cancer (1) 1
breast neoplasms - chemistry (1) 1
breast neoplasms - drug therapy (1) 1
breast neoplasms - mortality (1) 1
breast neoplasms - pathology (1) 1
cancer-patients (1) 1
carcinoma, ductal, breast - chemistry (1) 1
carcinoma, ductal, breast - mortality (1) 1
carcinoma, ductal, breast - pathology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 583 - 594
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2009, Volume 10, Issue 4, pp. 341 - 350
Journal Article
Cancer Letters, ISSN 0304-3835, 2014, Volume 354, Issue 2, pp. 365 - 377
Highlights • Gene expression profiles of cetuximab sensitive and resistant cells were compared. • Cetuximab resistant cells still exhibit RAS–MAPK signaling... 
Hematology, Oncology and Palliative Medicine | Head and neck squamous cell carcinoma | Aurora kinase B | Anti-EGFR therapy | Cetuximab resistance | NanoPro 1000 | Dual-specificity phosphatase 5 and 6 | GROWTH-FACTOR-RECEPTOR | APIGENIN INDUCES APOPTOSIS | PANCREATIC-CANCER | MONOCLONAL-ANTIBODY | MESENCHYMAL TRANSITION | NECK-CANCER | Nano Pro 1000 | TYROSINE KINASE INHIBITORS | ONCOLOGY | COLORECTAL-CANCER | AURORA KINASES | SQUAMOUS-CELL CARCINOMA | Phosphorylation | Aurora Kinase B - metabolism | Apoptosis - drug effects | Carcinoma, Squamous Cell - genetics | Humans | Middle Aged | Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors | Panitumumab | Drug Resistance, Neoplasm | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Squamous Cell Carcinoma of Head and Neck | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacology | Quinazolines - administration & dosage | Antineoplastic Agents - pharmacology | Head and Neck Neoplasms - enzymology | Cetuximab | Organophosphates - administration & dosage | Carcinoma, Squamous Cell - enzymology | Dual-Specificity Phosphatases - metabolism | Antibodies, Monoclonal - pharmacology | Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors | Head and Neck Neoplasms - drug therapy | Drug Synergism | Organophosphates - pharmacology | Carcinoma, Squamous Cell - drug therapy | MAP Kinase Signaling System - drug effects | Mitogen-Activated Protein Kinase 3 - metabolism | Cell Line, Tumor | Head and Neck Neoplasms - genetics | Quinazolines - pharmacology | Mitogen-Activated Protein Kinase 1 - metabolism | Antimitotic agents | Antineoplastic agents | Medical research | Chemotherapy | Rodents | Biomarkers | Cytotoxicity | Larynx | Mutation | Radiation therapy | Kinases | Cancer therapies | Tumors | Cancer
Journal Article
Cancer biotherapy & radiopharmaceuticals, ISSN 1084-9785, 09/2017, Volume 32, Issue 7, pp. 229 - 238
Aberrant signaling of the epidermal growth factor receptor (EGFR) plays a crucial role in the tumorigenesis of many cancer types, including head and neck... 
MEHD7945A | hypoxia | combination therapy | cetuximab resistance | head and neck squamous cell carcinoma | MEDICINE, RESEARCH & EXPERIMENTAL | ACQUIRED-RESISTANCE | ANTIBODY | DRUG-RESISTANCE | CANCER | FAMILY | EGFR INHIBITORS | THERAPY | MICROENVIRONMENT | ONCOLOGY | HNSCC | PHARMACOLOGY & PHARMACY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | ERBB RECEPTORS | Receptor, ErbB-3 - metabolism | ErbB Receptors - metabolism | Antibodies, Monoclonal - pharmacology | Carcinoma, Squamous Cell - metabolism | Humans | Head and Neck Neoplasms - drug therapy | Cetuximab - pharmacology | Cisplatin - pharmacology | Head and Neck Neoplasms - metabolism | Antineoplastic Agents, Immunological - pharmacology | Squamous Cell Carcinoma of Head and Neck | Carcinoma, Squamous Cell - drug therapy | Signal Transduction - drug effects | Cell Line, Tumor | Immunoglobulin G - pharmacology | Antineoplastic Agents - pharmacology | Drug Resistance, Neoplasm - drug effects | Biotechnology | Cytotoxicity | Kinases | Cancer therapies | Blockage | Human papillomavirus | Epidermal growth factor | Tumorigenesis | Growth factors | Drug dosages | Squamous cell carcinoma | Oxygen | Epidermal growth factor receptors | Tumor cell lines | Radiation therapy | Cisplatin | Studies | Signaling | Sensitivity | Chemotherapy | Cell lines | Monoclonal antibodies | Head and neck cancer | Hypoxia | Cancer | Tumors
Journal Article
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 1992, Volume 28, Issue 12, pp. 1971 - 1973
We report 2 patients who developed a borderline malignancy of the ovary after treatment with follicular stimulants in the context of an in vitro fertilisation... 
GONADOTROPIN THERAPY | ONCOLOGY | CARCINOMA | CANCER | TUMORS | Fertilization in Vitro | Chorionic Gonadotropin - adverse effects | Humans | Gonadotropin-Releasing Hormone - adverse effects | Adult | Female | Ovarian Neoplasms - chemically induced | Ovulation Induction - adverse effects | Menotropins - adverse effects | Ovarian Neoplasms - surgery
Journal Article
Annals of Oncology, ISSN 0923-7534, 1998, Volume 9, Issue 6, pp. 585 - 587
Journal Article
Annals of Oncology, ISSN 0923-7534, 2008, Volume 19, Issue 4, pp. 649 - 654
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.